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Abstract
Although CD81 has been shown to bind HCV E2 protein, its role as a receptor for HCV remains controversial. In this study, we
constructed two CD81 chimeras by linking the cytoplasmic domains of recycling surface receptors, low-density lipoprotein receptor
(LDLR), and transferrin receptor (TfR), respectively, to CD81 and compared their internalization properties to wild-type CD81. Binding
experiments with anti-hCD81 antibody showed that cell-surface CD81 chimeric receptors were internalized much more efficiently than
wild-type CD81. In addition, CD81 chimeras, but not wild-type CD81, could internalize recombinant E2 protein and E2-enveloped viral
particles from the serum of HCV-infected patients into Huh7 liver cells. The latter resulted in persistent positive-strand viral RNA and
accumulation of replication intermediates, negative-strand viral RNA, in the infected cells, suggesting that the internalized viruses have
undergone replication. Therefore, it appeared that CD81, possibly in association with a liver-specific endocytotic protein(s), represents one
of the pathways by which HCV can infect hepatocytes.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Hepatitis C virus (HCV), a positive-stranded RNA virus
of the family Flaviviridae, is the major cause of non-A,
non-B hepatitis worldwide (Houghton, 1996). The HCV
positive-stranded RNA genome encodes a precursor
polyprotein of 3000 amino acids (aa) that is processed
cotranslationally and posttranslationally to give rise to viral
structural and nonstructural proteins (for reviews see Bar-
tenschlager and Lohmann, 2000; Reed and Rice, 2000).
Two of the structural proteins, E1 and E2, interact to form
complexes that function as envelope proteins of HCV (Del-
eersnyder et al., 1997; Dubuisson, 2000; Dubuisson et al.,
1994; Flint and McKeating, 2000; Grakoui et al., 1993;
Ralston et al., 1993).
A member of the tetraspanin family, CD81, was identi-
fied as a putative receptor for HCV (Pileri et al., 1998). It
comprises four transmembrane domains with both N- and
C-termini positioned on the cytoplasmic side of the mem-
brane. It is expressed on the surface of various cell types and
is involved in a variety of biological functions (for review
see Levy et al., 1998). While the presence of antibodies
capable of inhibiting the binding of E2 to human cells was
correlated with natural resolution of chronic HCV infection
(Ishii et al., 1998), it remains unclear if CD81 is the receptor
for HCV entry into cells as CD81 is ubiquitously expressed
and thus cannot explain virus tropism to the liver. More-
over, in cell-fusion assays that used chimeric HCV envelope
proteins, overexpression of human CD81 did not affect
cell-fusion activity (Flint et al., 1999a; Takikawa et al.,
2000). Others also reported strong binding of HCV E2 to
CD81 of tamarins, although tamarins are apparently not
susceptible to HCV infection (Allander et al., 2000; Meola
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et al., 2000). Furthermore, several studies suggest that the
low-density lipoprotein receptor (LDLR) may also be a
potential receptor for HCV (Agnello et al., 1999; Jones et
al., 2000; Monazahian et al., 1999; Seipp et al., 1997;
Wu¨nschmann et al., 2000).
The process of receptor-mediated endocytosis, by which
cells internalize their plasma membrane together with mol-
ecules bound to cell-surface receptors, has been implicated
as the route of cell entry by several viruses, including rabies,
herpes-, Semliki Forest, and African swine fever viruses
(for reviews see Angulo et al., 1993; Brideau et al., 2000;
Gaudin et al., 1999; Kielian and Jungerwirth, 1990). It was
recently reported that CD81 has low internalization effi-
ciency, with only 30% of surface receptors being internal-
ized even after 12 h at 37°C (Petracca et al., 2000). This
may be one reason why CD81-overexpressing cells are only
moderately permissive and cannot be reproducibly infected
by HCV (for reviews see Flint and McKeating, 2000; Flint
et al., 2001; Rice, 1999).
To further examine the roles played by CD81 and endo-
cytosis in HCV cell entry, we constructed two CD81 chi-
meric receptors by linking either the N- or the C-terminus of
CD81 with the cytoplasmic domains of the transferrin re-
ceptor or LDLR, respectively. These two receptors are con-
stitutively clustered in coated pits and can be rapidly inter-
nalized, transported to the acidic endosome, and finally
recycled back to the cell surface (for review see Goldstein et
al., 1985). We compared the ability of wild-type CD81 and
CD81 chimeras to internalize surface-bound anti-hCD81
antibody or recombinant HCV E2 protein into a hepatoma
cell line, Huh7, and found that the CD81 chimeras possess
greater internalization efficiencies than wild-type CD81.
We further compared the internalization of HCV particles in
the sera of HCV-infected patients into the different Huh7
clones and found that although there were unspecific and
CD81-independent binding of HCV particles on the cell
surface, these unspecifically bound particles were not inter-
nalized into the cells. Instead, only E2-enveloped HCV-
particles that were bound to cell-surface CD81 chimeras
were internalized into the cells. No internalization of HCV
particles was observed for Huh7 cells overexpressing wild-
type CD81. Moreover, when the infected cells were further
cultivated for 7 to 21 days, persistent HCV positive-strand
viral RNA, as well as the replication intermediates, nega-
tive-strand viral RNA, could be detected in Huh7 cells
expressing the chimeric receptors, implying that the inter-
nalized viruses have undergone some degree of replication.
A difference in the sequence of the HCV E1/E2 region
between RNA extracted from the infected cells and from the
patient’s serum was also observed, providing further evi-
dence for viral replication. No internalization or replication
of HCV was observed if the serum was precleared with an
anti-HCV E2 antibody, indicating that the internalization is
dependent on the interaction between cell-surface CD81 and
E2 protein on the surface of HCV particles.
Results
High levels of CD81 expression on the surface of stable
Huh7 clones
Three stable Huh7 clones expressing different forms of
CD81 were established: wild-type CD81 (CD81WT), CD81
fused at the N-terminus with 61 aa of the cytoplasmic
domain of transferrin receptor (TfR-CD81), and CD81
fused at the C-terminus with 50 aa of the cytoplasmic
domain of LDL receptor (CD81-LDLR) (Fig. 1A and B).
These two cytoplasmic domains have been shown to contain
structural features required for coated pit-mediated endocy-
tosis of transferrin receptor (TfR) and LDLR, respectively
(for reviews see Goldstein et al., 1985; Pearse and Robin-
son, 1990; Trowbridge, 1991). The expressions of receptors
on the cell surfaces of untransfected and stably transfected
Huh7 clones were determined by FACS analysis using an-
tibodies specific for human CD81 (hCD81), LDLR, and TfR
(Fig. 1C). Untransfected Huh7 expressed low levels of
CD81, whereas all three stable clones (CD81WT, TfR-
CD81, and CD81-LDLR) showed high levels of surface
expression. We also compared the expression of endoge-
nous TfR and LDLR between untransfected Huh7 and the
three stable clones and found that their levels did not vary
significantly. 293T cells expressing endogenous CD81,
LDLR, and TfR were used as positive controls.
Chimeric receptors, TfR-CD81 and CD81-LDLR,
internalize more efficiently than CD81WT
After overlaying monolayers of the various Huh7 clones
with anti-hCD81 antibody for 1 h at 37°C, the amount of
antibody (IgG; only heavy chain detected) bound to the cell
surface or internalized into the cells was determined by
Western blot analysis (Fig. 2A). For one set of experiments,
the cells were washed with PBS only and then lysed and
analyzed for total amount of antibody bound, i.e., on the cell
surface and internalized. For the other set, the cells were
washed with cold acid to remove antibody bound on the cell
surface before cells were lysed and analyzed for internalized
antibody. As would be expected, strong binding of anti-
hCD81 antibody to Huh7-CD81WT, Huh7-TfR-CD81, and
Huh7-CD81-LDLR, but not untransfected Huh7, cells were
observed. After the acid wash to remove the anti-hCD81
antibody bound on the cell surfaces, 30% of the cell-
associated anti-hCD81 antibody (sum of surface-bound and
internalized antibodies, i.e., without acid wash, was normal-
ized to 100%) remained in the intracellular fractions of
Huh7-CD81WT cells (Fig. 2A). Any slight difference in the
number of cells used in each experiment was corrected by
comparing Hsp70 levels in the cell lysate. This observation
is similar to that of a recent study, which reported that only
30% of surface CD81 on a human B cells was internalized
after 4 h at 37°C and no further increase in this percentage
was observed even after 12 h at 37°C (Petracca et al., 2000).
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The faster rate of internalization in Huh7-CD81WT cells
observed here may be related to the cell-type or higher
surface expression of CD81. Exposure to antibody for more
than 1 h also did not result in a significant increase in
intracellular accumulation of anti-hCD81 antibody in Huh7-
CD81WT cells (data not shown). For Huh7-TfR-CD81 and
Huh7-CD81-LDLR cells, an even higher percentage
(70%) of anti-hCD81 antibody was internalized, showing
that the fusion of cytoplasmic domains from the two recy-
cling receptors, transferrin receptor and LDL receptor, to
CD81 have greatly increased the internalization efficiency
of the receptor (Fig. 2A). The fusion of these cytoplasmic
domains at the N-terminus (TfR-CD81) or C-terminus
(CD81-LDLR) of CD81 appeared to increase the internal-
ization of CD81 to a similar extent.
The binding and internalization of the different receptors
were also investigated using immunofluorescence methods.
Consistent with the above results (Figs. 1C and 2A), high
levels of surface expression of CD81 were detected in all
three clones (Huh7-CD81WT, Huh7-TfR-CD81, and Huh7-
CD81-LDLR) using indirect immunofluorescence after the
cells were incubated with anti-hCD81 antibody for 3 h at
4°C (Fig. 2B, top), followed by an FITC-conjugated anti-
mouse antibody. No staining was observed for the untrans-
fected Huh7 cells (data not shown). To determine the path
of the receptors after internalization, live cells were overlaid
with anti-hCD81 antibody for 1 h at 37°C, followed by acid
stripping of surface-bound antibody. The cells were then
permeabilized and probed with an FITC-conjugated anti-
mouse antibody for the presence of internalized anti-hCD81
antibody. For Huh7-TfR-CD81 and -CD81-LDLR cells,
bright punctuate intracellular stainings were observed,
showing that anti-hCD81 antibody was internalized and
transported to endosome-like structures (Fig. 2B, bottom).
Consistent with the lower internalization efficiency of wild-
type CD81, Huh7-CD81WT cells showed little uptake of
anti-hCD81 antibody in this experiment (Fig. 2B, bottom).
It should be noted that the measurement of intracellular
(i.e., non-acid removable) anti-hCD81 antibody as a probe
for the internalization of CD81 receptor is only comparative
and may be an underestimation as some of the internalized
antibody may be degraded. For example, the rapid degra-
dation of antibodies intracellularly after internalization by
LDLR and low-density lipoprotein receptor-related protein
(LRP) has been reported (Beisiegel et al., 1981; Davis et al.,
1987; Herz et al., 1990; van Driel et al., 1989).
Binding and internalization of a soluble form of HCV E2
protein in Huh7 stable clones
A secreted soluble form of E2, which lacks the C-termi-
nal hydrophobic transmembrane anchor (Selby et al., 1994),
was expressed in 293T cells using the pSecTag vector
(Invitrogen). Recombinant E2 protein was separated on
SDS–PAGE in the absence or presence of reducing agent
and subjected to Western blots analysis and the results are
shown in Fig. 3A; the left panel was probed with an anti-
c-myc monoclonal antibody (as E2 is fused with c-myc
epitope at the C-terminus) and the right panel was probed
with an anti-HCV E2 monoclonal antibody. In the absence
of reducing agents, the purified protein separated on SDS–
Polyacrylamide gel (PAGE) has two forms: a high molec-
ular weight species 111-kDa (80%) and an 70-kDa
species (20%) (Fig. 3A). The addition of reducing agents
(10 mM DTT and 20 mM beta-mercaptoethanol) resulted in
the dissociation of the higher molecular weight species to a
single 70-kDa band on SDS–PAGE (Fig. 3A). This suggests
that the majority of the purified E2 was in the form of
disulphide-linked aggregates, which could be dissociated by
the addition of reducing agent. Aggregates of E2 have been
reported in several studies (Deleersnyder et al., 1997; Flint
et al., 2000; Heile et al., 2000; Meyer et al., 2000; Michalak
et al., 1997). The monomeric E2 exhibited a lower mobility
(70 kDa) than the molecular weight predicted from the
peptide sequence (36 kDa), indicating that the protein was
heavily glycoslyated, consistent with previous reports (Gra-
koui et al., 1993; Hijikata et al., 1991a; Hsu et al., 1993;
Matsuura et al., 1992, 1994). It is noted that the anti-E2 and
anti-c-myc antibodies detected both monomeric and aggre-
gated forms of glycoslyated E2 protein. The anti-HCV E2
antibody can also be used to immunoprecipate viral parti-
cles from the serum of an HCV-infected patient (see below).
HCV E2 has been shown to be capable of binding to
CD81 in vitro (Flint et al., 1999b; Higginbottom et al.,
2000; Pileri et al., 1998). As it is difficult to separate the
monomeric and aggregated forms of the recombinant E2,
we used the mixed population of E2 proteins to overlay onto
monolayers of the various Huh7 clones to assess its binding
to the different cell-surface receptors. After that, the cells
were lysed in Laemmli’s SDS buffer with reducing agents
and boiled for 5 min to ensure that any E2 protein associated
(i.e., E2 bound on the cell surface or internalized) with the
cells were released into solution. Fig. 3B showed that E2
Fig. 1. CD81 wild-type and chimeric receptors. (A) Schematic diagram showing the membrane topologies of wild-type CD81 (CD81WT), transferrin receptor
(TfR), and low-density lipoprotein receptor (LDLR), and the predicted topologies of CD81 chimeras (TfR-CD81 and CD81-LDLR). (B) Schematic diagram
showing the construction of CD81 chimeras; TfR-CD81 is obtained by linking the cytoplasmic domain of TfR to the N-terminus of CD81 and CD81-LDLR
is obtained by linking the cytoplasmic domain of LDLR to the C-terminus of CD81. Hatched boxes represent the transmembrane domains and black boxes
represent the cytoplasmic domains of TfR and LDLR, which were fused to N - and C-terminus of CD81, respectively. (C) FACS analysis of the surface
expressions of CD81, TfR, and LDLR in untransfected Huh7 and stably transfected Huh7 clones. Cells were stained with specific antibodies (anti-hCD81,
anti-TfR, or anti-LDLR), followed by phycoerythrin-conjugated goat anti-mouse IgG (unfilled histograms). Filled histograms represented staining by
phycoerythrin-conjugated antibody alone. 293T cells expressing endogenous receptors were used as positive controls.
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Fig. 2. Internalization of anti-hCD81 antibody via cell-surface CD81 chimeras determined by two independent methods. (A) Cells were incubated with an
anti-hCD81 monoclonal antibody for 1 h at 37°C, followed by PBS washes or PBS and acid washes, and then cells were harvested after trypsinization and
directly lysed in Laemmli’s SDS buffer (containing reducing agents) and subjected to Western blot analysis. The cell lysate for cells that were only washed
with PBS would contain both surface-bound and internalized antibody (total). For cells that were subjected to an additional acid wash to remove
surface-bound antibody, the lysate would contain only internalized antibody (internalized). The heavy chain of the anti-hCD81 antibody (IgG heavy chain)
was detected by Western blot. CD81WT-, TfR-CD81-, and CD81-LDLR-expressing cells bound anti-hCD81 antibody (no binding to untransfected Huh7
cells), but only the chimeras efficiently internalized the surface-bound antibody. Expression of endogenous heat shock 70 protein, Hsp70, was used for
normalization. This experiment was repeated three times and similar results were obtained. A representative set of data is presented. (B) Top: Indirect
immunofluorescence analysis of wild-type and chimeric CD81 proteins expressed on the surface of Huh7 clones. Live cells were incubated with anti-hCD81
antibody for 3 h at 4°C, followed by an FITC-conjugated goat anti-mouse antibody for 2 h at 4°C. Cells were then fixed and surface expression of CD81
was visualized by confocal microscopy. Bottom: Live cells were incubated with anti-hCD81 antibodies for 1 h at 37°C to allow internalization of anti-hCD81
antibody that has bound to surface CD81 receptors. After that, the remaining surface-bound antibodies were washed away with acid and the cells were fixed,
permeabilized, and stained with an FITC-conjugated goat anti-mouse antibody to detect anti-hCD81 antibody that has been internalized into the cells.
bound to Huh7-CD81WT, Huh7-TfR-CD81, and Huh7-
CD81-LDLR, but not to untransfected Huh7 cells, suggesting
that the recombinant E2 protein can bind to the extracellular
domain(s) of CD81, which is present in all these stable clones.
However, the association rate appeared to be quite slow as
bound E2 protein was only detected after 4 h at 37°C. This is
likely due to the low concentration of monomeric E2 expressed
in our system as it has been shown that only monomeric E2
and not aggregated E2 oligomers is capable of binding CD81
(Flint et al., 2000; Petracca et al., 2000).
To determine if E2 protein was internalized, recombinant
E2 protein was again overlaid onto live cells for 4 h at 37°C,
followed by acid wash, cell fixation, and permeabilization
before detection of internalized E2 by indirect immunoflu-
orescence. Consistent with the antibody internalization ex-
periments, E2 protein was found in bright punctuate intra-
cellular structures in the cytoplasm of Huh7-TfR-CD81 and
Huh7-CD81-LDLR cells, but not in Huh7-CD81WT cells
(Fig. 3C), showing that the chimeric CD81 receptors were
more efficient in internalizing surface-bound E2 protein.
Although we cannot rule out that there may be small
amounts of E2 protein internalized into Huh7-CD81WT
cells, any accumulated amount was too low to be detected
by indirect immunofluorescence.
Chimeric receptor, TfR-CD81, mediates the entry of E2-
enveloped HCV particles into Huh7 cells
Next, we tested the ability of the stable Huh7 clones to
mediate HCV entry. Serum from a HCV-infected patient
(patient A) was overlaid onto untransfected Huh7 or Huh7-
CD81WT or Huh7-TfR-CD81 cells for a period of 8 h,
after which these cells were washed extensively with PBS
and harvested by scrapping. For another set, the cells were
further washed with cold acid for 5 min to remove viral
particles bound on the cell surface before the cells were
harvested. To conserve the limited amount of patient’s se-
rum for further experiments, we did not include the Huh7-
CD81-LDLR cells in this first set of experiments, as the
chimeric receptor CD81-LDLR was shown to have very
similar binding and internalization properties as TfR-CD81
in the above experiments. Total RNA was subsequently
extracted from the cells and nested RT-PCR was performed
to assay for the presence of HCV-specific positive-strand
viral transcripts. Total cellular protein was also extracted
from the same cells and Western blot analysis was per-
formed to determine the uptake of HCV E2 proteins from
patient’s serum into the cells. As the genotypes were ini-
tially not known, the sequences of primers used for RT-PCR
were chosen from regions in 5 noncoding region (5NCR)
that are well conserved between all known HCV variants
(Bukh et al., 1992; Chan et al., 1992; Garson et al., 1990;
Okamoto et al., 1990). These primers (Table 1) correspond
to nucleotide positions (nt) 36 to 73 (sense) and nt 331 to
279 (antisense) of representative 1b isolate HCV-BK (Taka-
mizawa et al., 1991; GenBank Accession No. M58335) and
are similar to the ones commonly used in the literature for
genotyping of HCV isolates.
HCV-specific positive-strand RT-PCR products were ob-
served for untransfected Huh7, Huh7-CD81WT, and Huh7-
TfR-CD81 cells when the cells were washed only with PBS,
showing that a significant amount of HCV particles were
bound to these cells and the binding of these HCV RNA-
containing particles were not dependent on the surface ex-
pression of CD81 (Fig. 4A, lanes 2, 4, and 6). No products
were obtained for untransfected Huh7 cells that were not
exposed to HCV particles (Fig. 4A, lane 1). A strong signal
was also observed when RT-PCR was carried out using
RNA extracted from an equivalent amount of patient’s se-
rum that was used for each plate of cells (10 l) (Fig. 4A,
lane 8). For controls, RNA extracted from untransfected
293T cells and 293T cells that were transfected with cDNA
encoding a HCV full-length genome (Lim et al., 2001),
respectively, were used (Fig. 4A, lanes 9 and 10). This may
suggest that there are other HCV-binding receptors on the
surface of Huh7 cells and this binding is independent of
HCV E2 glycoprotein as recombinant HCV E2 only bound
to Huh7-CD81WT and Huh7-TfR-CD81 but not to untrans-
fected Huh7 cells (Fig. 3B). Alternatively, this could be due
to some unspecific binding of some HCV particles to the
cell surface. However, Western blot analysis showed that
HCV E2 proteins were present in Huh7-CD81WT and
Huh7-TfR-CD81 cells, but not in untransfected Huh7 cells,
after they were overlaid with the patient’s serum (Fig. 4B,
lanes 2, 4, 6), suggesting that there is a population of HCV
E2-enveloped viral particles in the patient’s serum and these
particles bound specifically to the cell-surface CD81 recep-
tors.
When an acid wash was used to remove any surface-
bound HCV particles, HCV-specific positive-strand RT-
PCR products were detected only in Huh7-TfR-CD81 cells
but not in untransfected Huh7 or Huh7-CD81WT cells (Fig.
4A, lanes 3, 5, and 7). HCV E2 protein was again detected
only in Huh7-TfR-CD81 cells after the acid wash (Fig. 4B,
lane 7), suggesting that E2-enveloped viral particles were
internalized into these cells. In contrast, no HCV E2 protein
was detected in the Huh7-CD81WT cells after the acid wash
(Fig. 4B, lane 5), indicating E2-enveloped viral particles
that bound to the surface of these cells were not internalized.
Therefore, consistent with the E2-binding studies de-
scribed above, only Huh7-TfR-CD81 cells displayed the
ability to internalize E2-enveloped HCV particles via the
interaction between viral envelope protein E2 and cell-
surface CD81 molecules. Huh7-CD81WT cells, on the other
hand, could bind E2-enveloped viral particles on the cell
surface but were not capable of internalizing the viral par-
ticles. Untransfected Huh7 cells did not bind any E2-envel-
oped viral particles but bound HCV RNA-containing parti-
cles, which were not enveloped by the E2 protein. These
nonenveloped viral particles bound to a (unknown) surface
receptor(s) other than CD81 but this receptor was not ca-
pable of internalizing the HCV particles bound to it.
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Fig. 3. Internalization of recombinant E2 protein into Huh7 cells expressing CD81 chimeras. (A) Recombinant E2 protein, fused at the C-terminus with a
myc-epitope and a (His)6 motif, was expressed in 293T cells and purified with NTA beads. The protein was then separated on SDS–PAGE in the absence
or presence of reducing agents and detected by Western analysis using an anti-c-myc antibody (left panel) or an anti-HCV E2 antibody (right panel). Control
cells were transfected with vector only (Vec). Under nonreducing conditions, E2 exists mainly as high molecular weight aggregates and only a small
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HCV internalized into Huh7 cells via chimeric receptor,
TfR-CD81, can undergo replication
To determine if HCV internalized into Huh7-TfR-CD81
cells can undergo replication, the overlay experiments were
repeated but the cells were cultivated for another 7 days after
infection. After that, the cells were harvested and analyzed for
the presence of positive- and negative-stranded HCV RNA.
The volume of patient’s serum (patient A) used was increased
by 10 times to increase the amount of virus particles that can
be internalized into Huh7-TfR-CD81 cells. Fig. 5A showed
that, after 7 days of cultivation, no HCV-specific positive-
strand RT-PCR product was detected for untransfected Huh7
or Huh7-CD81WT cells but a strong signal was observed for
Huh7-TfR-CD81 cells (Fig. 5A, lanes 1–3, panel I). In com-
parison to the overlay experiment described above where the
cells were harvested after 8 h (Fig. 4, lanes 2 and 4), HCV
particles that were bound on the surface of untransfected Huh7
and Huh7-CD81WT cells were no longer detected, suggesting
that they were degraded after further cultivation of the cells
(Fig. 5A, lanes 1 and 2, panel I). On the other hand, HCV
particles that were internalized into Huh7-TfR-CD81 cells
were not degraded and a significant amount of HCV RNA was
still present after the cells were cultivated for 7 days. The
presence of negative-strand RNA, which is an indicator of
active viral replication, was examined using the strand-specific
tagged RT-PCR method devised by Lanford et al. (1994).
Again, no product was obtained for untransfected Huh7 and
Huh7-CD81WT cells, whereas Huh7-TfR-CD81 cells showed
a weak RT-PCR product under UV light after staining with
ethidium bromide (Fig. 5A, lanes 1–3, panel III). Further con-
firmation was obtained by Southern blot analysis (Fig. 5A,
lanes 1–3, panel IV). The persistence of positive-strand RNA
and the presence of negative-strand RNA indicate that HCV
internalized into Huh7-TfR-CD81 cells have undergone repli-
cation, albeit at a low level.
Table 1
Primers used for the cloning of constructs and the detection of viral transcripts
Name Sequence (5 to 3)
C1 AAAGCTAGCGGATCCGCCACCATGGGAGTGGAGGGCTGCACCAAGTGCATCAAGT
C2 AAAGAATTCGCGGCCGCTCAGTACACGGAGCTGTTCCGGATGCCACAGCACAGCACCATGCTCAG
C3 CCCAAGCTTACCATGGCGATGATGGATCAAGCTAGATCAGCA
C4 CGCGGATCCCCTTTTTGGTTTTGTGACATTGGC
C5 CCGGAATTCAAGAACTGGCGGCTTAAGAACATC
C6 ATAAGAATGCGGCCGCTCACGCCACGTCATCCTCCAG
C7 GGGGGATCCACCACACCCAAGTGATGGGGG
C8 GGGGATATCTCTCTGATCTATCCCTGTCCTC
209b ATACTCGAGGTGCACGGTCTACGAGACCT (nt 331–312)a
939c CTGTGAGGAACTACTGTCTT (nt 36–55)a
211b CACTCTCGAGCACCCTATCAGGCAGT (nt 294–279)a
940c TTCACGCAGAAAGCGTCTAG (nt 54–73)a
E1E2R1 TCCTGTTGATGTGCCAGCT (nt 1605–1587)
E1E2F1 TCCCAGCTGTTCACCTTCT (nt 1194–1212)
E1E2R2 TGCCAGCTGCCGTTGGTGTTTA (nt 1594–1573)
E1E2F2 TTCTCACCTCGCCGGTATGAGA (nt 1209–1230)
TAGNC1 TCATGGTGGCGAATAAACTCCACCATAGATCACTCC (nt 15–34)a
TAG TCATGGTGGCGAATAA
HCVprobe GCAGAAAGCGTCTAGCCATGGCGTTAGTAT (nt 59–88)a
GAPDHfor CTGAGAACGGGAAGCTTGTCATCA
GAPDHrev CGTCTAGCTCAGGGATGACCTTG
a All HCV nucleotide positions (nt) are reference to a representative genotype 1b isolate, HCV-BK (Takamizawa et al., 1991, Genbank Accession No.
M58335). Sequences corresponding to restriction sites are indicated in italics.
b Sequence is the same as primers used in Garson et al. (1990).
c Sequence is the same as primers used in Okamoto et al. (1990).
percentage exists as monomers. In the presence of reducing agents, most of the aggregates dissociated to form monomers. There were also some unresolved
proteins (probably larger aggregates of E2 protein) at the top of the gel (data not shown). (B) Recombinant E2 proteins were overlaid onto monolayers of
the various clones at 37°C for 4 h. Then the cells were washed with PBS, harvested after trypsinization, and directly lysed in Laemmli’s SDS buffer containing
reducing agents to release any E2 associated with the cells, i.e., surface-bound and internalized protein, and an anti-c-myc antibody used to detect E2 protein
in the total cell lysate. Binding of E2 protein to Huh7 stable clones overexpressing wild-type or chimeric CD81 were observed but no binding to untransfected
Huh7 cells was observed. Beta-actin expression showed equal loading of total cell lysate. (C) Recombinant E2 proteins were overlaid onto monolayers of
Huh7-CD81WT, Huh7-TfR-CD81, or Huh7-CD81-LDLR cells for 4 h at 37°C. Then the cells were washed for 5 min with acid to remove surface-bound
protein and then permeabilized and probed with anti-c-myc antibody to examine for internalized E2 proteins. In both Huh7-TfR-CD81 and Huh7-CD81-
LDLR cells, but not Huh7-CD81WT cells, transportation of E2 from the surface to intracellularly punctuate structures was observed. Some weak background
staining was observed in all cells, including Huh7 stable clones that have not been exposed to E2 protein (data not shown), and this may be due to the staining
of endogenous c-myc protein by the antibody used.
257Y.-J. Tan et al. / Virology 308 (2003) 250–269
When the same experiments were performed with serum
from another patient (patient B), we initially found no pos-
itive-strand RT-PCR products for untransfected Huh7 or
Huh7-CD81WT or Huh7-TfR-CD81 cells 7 days after in-
fection (Fig. 5B, lanes 1–3, panel I). As it has been reported
that some virus particles in patient sera are heavily coated
with lipoproteins and/or antiviral antibodies (IgG) (Agnello,
1995; Hijikata et al., 1993; Prince, 1994; Prince et al., 1996;
Seipp et al., 1997; Thomssen et al., 1992, 1993), we re-
peated the experiment after treating the patient’s serum with
0.05% of a mild detergent, deoxychloate. This method was
reported to remove lipoproteins/IgG gently from virus par-
ticles, resulting in enveloped virions, which can be trapped
onto grids by an anti-HCV E2 antibody and visualized with
electron microscopy (Prince et al., 1996). Remarkably, after
the detergent treatment, efficient uptake of viral particles
was observed for Huh7-TfR-CD81 cells but not for untrans-
fected Huh7 or Huh7-CD81WT cells (Fig. 5B, lanes 4–6,
panel I). Negative-strand RNA was also detectable only in
Huh7-TfR-CD81 cells (Fig. 5B, lane 6, panel III and IV),
again, implying that HCV internalized via TfR-CD81 chi-
meric receptors can undergo replication in Huh7 cells.
Positive-strand RT-PCR products from patients A and B
(Huh7-TfR-CD81 cells) were ligated into the pCRII-TOPO
vector (Invitrogen, Carlsbad, CA, USA) and the sequences
of the inserts were determined. Sequence of the RT-PCR
product (205 bp) from patient A is identical to the corre-
sponding 5NCR region of representative genotype 1b,
HCV-BK, sequence (Takamizawa et al., 1991; GenBank
Accession No. M58335) and that of patient B shows two
mismatches (Fig. 5C). Therefore, both patients A and B
were most likely to be infected with HCV genotype 1b.
Positive- and negative-strand HCV RNA in infected
Huh7-TfR-CD81 cells persisted for at least 21 days and
exhibited changes in the HCV E1/E2 region
To determine the stability and replication of HCV RNA
that have been internalized into Huh7-TfR-CD81 cells, 7
days after infection with serum from patient A, the cells
were subcultured into new plates and allowed to grow for
another 7 days, and the process repeated again after another
7 days. The presence of positive- and negative-strand HCV
RNA in the infected Huh7-TfR-CD81 cells at these differ-
ent time points were then determined by nested RT-PCR. As
shown in Fig. 6A (left panel), positive-strand HCV viral
transcripts were detected at day 0 (i.e., immediately after 8 h
of infection, P0), day 7 (P1), day 14 (P2), and day 21 (P3),
as well as in the patient’s serum (Serum). Similar results
were obtained using either primers corresponding to the
HCV 5NCR or E1/E2 region. On the other hand, negative-
strand HCV viral transcripts were detected neither at P0 nor
in the serum from the patient, but were detected at P1, P2,
and P3 (Fig. 6A, right panel). Again, similar results were
obtained using both sets of primers. In our hands, the tagged
RT-PCR method for detection of negative-strand HCV
RNA is specific as both Serum and P0 showed strong nested
RT-PCR signals only for positive-strand and not for nega-
tive-strand viral transcripts.
Next, we compared the sequences of negative and posi-
tive HCV RNA in the infected Huh7-TfR-CD81 cells at day
21 (P3) by sequencing individual clones obtained from the
Fig. 4. Binding and internalization of HCV particles. (A) Nested RT-PCR
was performed to assay for the presence of HCV positive-strand RNA in
untransfected Huh7, Huh7-CD81WT, and Huh7-TfR-CD81 cells after they
were exposed to serum from a HCV-infected patient (Patient A). HCV-
specific positive-strand PCR products were observed for all the cells (lanes
2, 4, and 6), suggesting that there was CD81-independent binding of HCV
particles onto the cell surface. However, after an acid wash to remove
surface-bound virus, positive-strand RT-PCR products were only observed
in Huh7-TfR-CD81 cells (lanes 3, 5, and 7), indicating that HCV particles
were internalized into Huh7-TfR-CD81 cells and not untransfected Huh7
or Huh7-CD81WT cells. No RT-PCR product was observed for untrans-
fected Huh7 cells that were not exposed to patient’s serum (lane 1).
Positive-strand RT-PCR products were also observed when the RNA from
an equivalent amount of patient’s serum (10 l) was used as the template
(lane 8). Control lanes 9 and 10 were loaded with RT-PCR products
obtained from RNA of untransfected 293T cells and 293T cells that were
transfected with cDNA encoding a HCV full-length genome, respectively.
DNA marker is shown on the left (nt, nucleotides) and cellular GAPDH
mRNA was used to check that a similar number of cells was used in the
experiments. (B) Western blot analysis was performed to determine if
E2-enveloped HCV particles could be internalized into the cells. Total
cellular protein was extracted from the same cells that were used for RNA
extraction above and subjected to Western blot analysis using an anti-HCV
E2 antibody. Huh7-CD81WT and Huh7-TfR-CD81 cells specifically
bound E2-enveloped viral particles as HCV E2 proteins were detected in
these cells (lanes 4 and 6). No binding of E2-enveloped viral particles was
observed for untransfected Huh7 cells (lane 2). E2-enveloped viral parti-
cles were internalized specifically into Huh7-TfR-CD81 cells as HCV E2
protein was detected in Huh7-TfR-CD81 cells (lane 7) but not in Huh7-
CD81WT cells (lane 5) after an acid wash to remove surface-bound viral
particles. Lane 8 showed the amount of E2 protein found in the patient’s
serum. Expression of actin showed equal loading and the high level of
albumin present in the patient’s serum was also detected (bottom).
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respective RT-PCR products. Using primers from the HCV
E1/E2 region, all the clones (41 clones were sequenced)
from the positive-strand RNA extracted from the patient’s
serum have the same sequence (Fig. 6B, Serum). On the
other hand, for negative-strand RNA extracted from the
infected Huh7-TfR-CD81 cells (P3), 10 of 33 clones (30%)
showed one or more nucleotide substitutions when com-
pared to the RNA extracted from the patient’s serum. Two
of these were silent mutations, i.e., the substitutions did not
result in any changes in the amino acid sequence, while
eight of these resulted in amino acid substitutions (Fig. 6B,
c.f., Serum and Negative-1 to -6). For “Negative-1” and
“Negative-2,” these sequences were found in two indepen-
dent clones. For the positive-strand RNA (Huh7-TfR-CD81
cells, P3), 6 of 66 clones (9%) showed nucleotide substitu-
tions, and one of these was a silent mutation, while the other
five resulted in amino acid changes (see Fig. 6B, c.f. Serum
and Positive-1 to -5). These results suggest that there was
some degree of replication occurring in the infected TfR-
CD81-Huh7 cells as the HCV E1/E2 region, in particular
the HVR1 region has been reported to be most susceptible
to sequence changes during the viral replication cycle (Hi-
jikata et al., 1991b; Weiner et al., 1991).
In contrast, for the 5NCR of the positive- and negative-
strand RNA in the infected Huh7-TfR-CD81 cells, all the
clones picked (20 clones for positive and 32 clones for
negative) have the same sequence as that of the positive-
strand RNA extracted from the patient’s serum (data not
shown).
Preclearing of patient’s serum with an anti-E2 antibody
abolished the internalization of HCV particles into Huh7-
TfR-CD81 cells
The remaining serum from patient A was frozen after the
overlay experiments described above. Here, the serum was
thawed and used to test if an anti-HCV E2 antibody, which
can detect glycoslyated E2 proteins (see Fig. 3A, right
panel), can immunoprecipate HCV particles from the se-
rum. After incubating the serum with anti-HCV E2 antibody
or control antibody (anti-c-myc antibody) and protein A/G
beads, the beads were washed, RNA extracted, and RT-PCR
performed to detect for positive-strand HCV RNA bound to
the beads. As shown in Fig. 7A, some HCV RNA was
immunoprecipitated by both the anti-HCV E2 (lane 6) and
the anti-c-myc (lane 2) antibodies. However, when we di-
luted the extracted RNA by 10, 30, and 100 before
performing the RT-PCR, RT-PCR products were observed
only for anti-HCV E2 antibody (lanes 7–9) at 10 and 30
dilutions but not for control anti-c-myc antibody (lanes
3–5), showing that the amount of HCV particles immuno-
precipitated with the anti-HCV E2 antibody was 10 to 30
times higher than with anti-c-myc antibody (Fig. 7A).
The sera precleared with anti-HCV E2 or anti-c-myc
antibodies were then used for overlaying onto Huh7-TfR-
CD81 cells. The cells were further cultivated for 7 days and
then tested for the presence of positive-strand HCV RNA as
before. As shown in Fig. 7B, preclearing with an anti-HCV
E2 antibody removed significant amount of viral particles
from the serum such that no positive-strand RT-PCR was
observed in Huh7-TfR-CD81 cells (Fig. 7B, lane 5). In
contrast, positive-strand RT-PCR product was clearly de-
tected when the serum was precleared with anti-c-myc an-
tibody (Fig. 7B, lane 6). Therefore, the internalization of
HCV particles into Huh7-TfR-CD81 cells is dependent on
the interaction between viral envelope protein E2 and cell-
surface CD81 molecules.
Here, we also repeated the infection experiments to com-
pare internalization and replication of virus particles in
untransfected Huh7, Huh7-CD81WT, Huh7-TfR-CD81,
and Huh7-CD81-LDLR cells. Huh7-CD81-LDLR cells
were not used in the first two overlay experiments described
in Fig. 5A and B. The results showed that positive-strand
RT-PCR products were observed in Huh7-TfR-CD81 and
Huh7-CD81-LDLR cells, but not in untransfected Huh7 or
Huh7-CD81WT cells (Fig. 7B, lanes 1–4). Therefore, in
three independent experiments (using sera from two differ-
ent HCV-infected patients), internalization of HCV parti-
cles (as indicated by the presence of positive-strand viral
RNA in the cells after 7 days of cultivation) into Huh7-TfR-
CD81 cells was consistently observed but no internalization
was observed for untransfected Huh7 or Huh7-CD81WT
cells. In one experiment, internalization of HCV particles
into Huh7-CD81-LDLR cells was also observed.
Discussion
The rapid internalization of cell-surface receptors, which
constitutively cluster in coated pits, is mediated by struc-
tural features in their cytoplasmic domains (for reviews see
Goldstein et al., 1985; Pearse and Robinson, 1990; Trow-
bridge, 1991). Furthermore, several studies have shown that
“tyrosine internalization signals” are self-determined struc-
tural motifs that could be transferred into proteins not nor-
mally endocytosed and would then confer recycling prop-
erties to these molecules (Collawn et al., 1991; Ktistakis et
al., 1990; Roth et al., 1986). CD81 has short N-terminal and
C-terminal cytoplasmic domains and is poorly internalized
(Petracca et al., 2000 and data herein). As demonstrated
here, when the cytoplasmic domains of the transferrin and
LDL receptors were linked to the N- and C-termini, respec-
tively, of wild-type CD81, these chimeric receptors (TfR-
CD81 and CD81-LDLR) showed significantly increased
endocytosis, indicating that the additional sequences are
sufficient to bring CD81 to the coated pits to allow endo-
cytosis (Fig. 2).
CD81 has been suggested to be a possible receptor for
HCV cell entry by virtue of its ability to specifically bind
HCV envelope E2 protein in vitro (Flint et al., 1999b;
Higginbottom et al., 2000; Pileri et al., 1998). In our present
study, we found that recombinant E2 protein bound to Huh7
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Fig. 5. Internalization and replication of HCV in Huh7-TfR-CD81 cells. Nested RT-PCR was performed to assay for the presence of viral transcripts in Huh7
stables clones after they were exposed to sera from two HCV-infected patients (A and B) for 8 h at 37°C, followed by cultivation for another 7 days to allow
viral replication. Cellular GAPDH mRNA was used to check that a similar number of cells was used in the experiments (A and B, panel II). (A) After the
cells were exposed to serum from patient A, a significant amount of positive-strand HCV RNA was detected in Huh7-TfR-CD81 cells but not in untransfected
Huh7 and Huh7-CD81WT cells (lanes 1–3, panel I, positive-strand RT-PCR products visualized under UV light after ethidium bromide staining).
Negative-strand HCV RNA was also detected only in Huh7-TfR-CD81 cells (lane 3, negative-strand RT-PCR products visualized under UV light after
ethidium bromide staining (panel III) and analyzed by Southern blot analysis with a HCV-specific probe (panel IV)). (B) No positive- or negative-strand viral
transcripts were detected in untransfected Huh7, Huh7-CD81WT, or Huh7-TfR-CD81 cells when serum from patient B was used directly to overlay onto the
cells (lanes 1–3, panels I, III, and IV). When the serum was pretreated with 0.05% deoxychloate before overlaying on the cells, positive-strand RT-PCR
products were observed in Huh7-TfR-CD81 but not in untransfected Huh7 and Huh7-CD81WT cells (lanes 4–6, panel I). Negative-strand RT-PCR can be
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stable clones that overexpress CD81WT, TfR-CD81, or
CD81-LDLR, but not to untransfected Huh7, which ex-
presses very low levels of CD81 (Fig. 3B). Consistent with
the higher internalization efficiency of the chimeric CD81
receptors, internalization of E2 protein was observed in
Huh7-TfR-CD81 and Huh7-CD81-LDLR cells but not in
Huh7-CD81WT cells (Fig. 3C).
Next, we examined if wild-type CD81 or the chimeric
CD81 receptors can bind and internalize viral particles in
the serum of an HCV-infected patient (patient A). Interest-
ingly, HCV-specific positive-strand viral transcripts were
found in untransfected Huh7 cells as well as in Huh7-
CD81WT and Huh7-TfR-CD81 cells after the cells were
overlaid with serum from a HCV-infected patient, suggest-
ing that some HCV RNA-containing particles can bind to
the cell surfaces in a CD81-independent manner (Fig. 4A,
lanes 2, 4, and 6). However, only Huh7-CD81WT and
Huh7-TfR-CD81 cells displayed the capability to bind HCV
E2-enveloped particles from the serum as HCV E2 proteins
were detected only in these cells and not in untransfected
Huh7 cells (Fig. 4B, lanes 2, 4, and 6). It is not surprising
that some non-E2-enveloped particles were found in the
patient’s serum as several studies have reported the pres-
ence of partially enveloped or nonenveloped HCV nucleo-
capsids in patient’s sera (Kanto et al., 1994, 1995; Maillard
et al., 2001; Nagasaka et al., 1997; Watson et al., 1996).
Using an acid wash to remove surface-bound viral particles,
we further demonstrated that surface-bound E2-enveloped
HCV particles were internalized into Huh7-TfR-CD81
cells, but not into Huh7-CD81WT cells, confirming that
internalization was occurring via endoctyosis of the chi-
meric TfR-CD81 receptors (Fig. 4A and B, lanes 5 and 7).
Further cultivation of the cells for 7 days after infection
also resulted in the degradation of surface-bound viral par-
ticles (both E2-enveloped and nonenveloped), as positive-
strand viral transcripts were no longer detected in untrans-
fected Huh7 cells and Huh7-CD81WT cells (Fig. 5A, lanes
1 and 2). On the other hand, both positive- and negative-
strand viral transcripts were detectable in Huh7-TfR-CD81
cells, suggesting that the internalized HCV has undergone
replication (Fig. 5A, lane 3). Moreover, the positive- and
negative-strand RNA persisted for at least 21 days in the
infected cells (Fig. 6A). When the sequences of the E1/E2
region of the HCV RNA in the infected cells (at day 21, P3)
were compared to the same region in the RNA from the
patient’s serum, there are significant changes, in particular,
for the negative-strand RNA (Fig. 6B). Thirty percent and
nine percent of the clones for the negative- and positive-
strand RNA, respectively, showed one or more nucleotide
substitutions, and the majority of these resulted in amino
acid changes when compared to positive-strand RNA ex-
tracted from the patient’s serum. It is unlikely that the
sequence heterogeneity is introduced during the PCR reac-
tion as the sequences of all the clones obtained from the
positive-strand RNA in the patient’s serum are identical (41
clones). In all cases, none of the clones from the HCV
5NCR region showed any difference. Taken together, these
results suggested that HCV internalized into Huh7-TfR-
CD81 cells have undergone replication. However, the
amino acid changes for both the positive- and the negative-
strand RNA are found randomly in the E1/E2 region (1–114
amino acids), rather than in the HVR1 region (Hijikata et
al., 1991b; Weiner et al., 1991), which corresponded to the
last 28 amino acids of this region (Fig. 6B). This may
suggest that replication in Huh7 cells is somewhat limited.
When the infection experiments were repeated with the
serum from another patient (patient B, Fig. 5B), the inter-
nalization of viral particles into Huh7-TfR-CD81 cells was
only observed after the serum was pretreated with a low
concentration of deoxychloate to release HCV particles
from bound lipoproteins (Prince et al., 1996). Therefore, it
appears that most of the viral particles in the serum from
patient B were probably coated with lipoproteins and/or
IgG, as has been previously reported (Agnello, 1995; Hi-
jikata et al., 1993; Prince, 1994; Prince et al. 1996; Seipp et
al., 1997; Thomssen et al., 1992, 1993). Since it has been
shown that CD81 binds to E2 and not to lipoproteins-bound
HCV particles (Wu¨nschmann et al., 2000), binding and
internalization of the HCV particles in the serum from
patient B, via E2–CD81 interaction, into Huh7-TfR-CD81
cells was only observed when these “interfering” molecules
were removed. Serum from patient A, on the other hand,
seems to contain sufficient “LDL-free” and E2-enveloped
HCV particles, such that internalization into Huh7-TfR-
CD81 and Huh7-CD81-LDLR cells were observed without
prior treatment of the serum. Interestingly, several reports
have correlated the physicochemical properties of HCV
particles in the sera with the disease status of the patients
(Kanto et al., 1994, 1995; Nagasaka et al., 1997; Watson et
al., 1996). It would be informative to know the proportion of
LDL-free HCV particles in the infectious chimpanzee sera
from Pileri et al. (1998), which were able to interact with
CD81.
Preclearing of the serum from patient A with an anti-
HCV E2 antibody efficiently removed HCV particles so that
no internalization of viral RNA was observed for Huh7-
TfR-CD81 cells (Fig. 7B), suggesting that HCV E2 protein
is the direct ligand for CD81, in agreement with previous
detected under UV light after ethidium bromide staining (panel III) and by Southern blot analysis (panel IV), only for Huh7-TfR-CD81 cells (lane 6). (C)
Positive-strand RT-PCR products from Huh7-TfR-CD81 cells that were overlaid with the serum from patient A or B were ligated into pCRII-TOPO vector
and sequenced from both directions. Sequences were aligned and compared with the corresponding 5 noncoding region from representative isolates,
HCV-BK for genotype 1b (Takamizawa et al., 1991; GenBank Accession No. M58335) and HCV-1 for genotype 1a (Choo et al., 1991; GenBank Accession
No. M62321). Nucleotides matching to HCV-BK are represented by () and mismatches are boxed. Nucleotide numberings shown on the left refer to the
nucleotide positions in HCV-BK.
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Fig. 6. Replication of HCV in infected Huh7-TfR-CD81 cells over 21 days. (A) Nested RT-PCR was performed to assay for the presence of viral transcripts
in Huh7-TfR-CD81 cells that were exposed to serum from patient A. Cells were collected after 8 h of overlay (P0) or allowed to grow for another 7 days
(P1), after which the 10% cells were subcultured onto new plates and allowed to grow and the rest of the cells were harvested for RNA extraction. Another
7 days later, i.e., 14 days after infection (P2), the cells were subcultured and collected as before and finally, at 21 days (P3), all the cells were collected. The
left panel showed the negative-strand RNA viral transcripts detected in the cells at P0, 1, 2, and 3, using nested RT-PCR with primers from the HCV E1/E2
region or 5NCR. The right panel showed the nested RT-PCR products from the positive-strand RNA obtained from the same cells and again, using two sets
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studies (Flint et al., 1999b; Higginbottom et al., 2000; Pileri
et al., 1998). Together with the overlay experiments (Fig.
4A and B), it is clear that the binding and internalization via
the chimeric CD81 receptors is specific for E2-enveloped
HCV particles and these receptors may not bind defective
particles, similar to partially enveloped or nonenveloped
nucleocapsids, which have been found in the serum of some
infected patients (Kanto et al., 1994, 1995; Maillard et al.,
2001; Nagasaka et al., 1997; Watson et al., 1996).
Numerous groups have suggested the LDLR as a likely
receptor for HCV cell entry (Agnello et al., 1999; Monaza-
hian et al., 1999; Seipp et al., 1997) and showed that there
is direct interaction between HCV envelope proteins and
lipoproteins, and thus, complexes of HCV and lipoproteins
can enter cells via LDLR-mediated endocytosis (Jones et
al., 2000; Monazahian et al., 2000). In our system, LDLR
appeared not to be important for mediating viral entry, as
comparable endogenous LDLR expression was observed in
both untransfected Huh7 and the various Huh7 stable clones
used in our studies (Fig. 1C), but the internalization of HCV
particles was only efficient in Huh7-TfR-CD81 and Huh7-
CD81-LDLR cells (Figs. 4, 5, and 7). One possible reason
for the lack of internalization of lipoprotein-bound HCV
particles into Huh7 cells is that lipoproteins from the FBS
employed for cell culture may be bound to the LDLR on the
cell surface and block the interaction between lipoprotein-
bound HCV particles and LDLR, as it has been shown that
free lipoproteins can competitively inhibit HCV entry
(Favre et al., 2001; Monazahian et al., 1999; Wu¨nschmann
et al., 2000).
In summary, we found that the overexpression of wild-
type CD81 on the cell surface was not sufficient for facili-
tating the entry of HCV particles into Huh7 cells, which is
in agreement with several recent reports that interaction
between CD81 and HCV E2 is not sufficient to confer
infectivity by HCV (Allander et al., 2000; Meola et al.,
2000). However, by engineering endocytotic signal tags
from transferrin and LDL receptors into either the N- or the
C-terminus cytoplasmic domains of CD81, we were able to
trigger the uptake of E2-enveloped viral particles into Huh7
cells. Both chimeric receptors, TfR-CD81 and CD81-
LDLR, internalized HCV particles (as indicated by the
persistence of intracellular positive-strand HCV RNA
and/or by the presence of HCV E2 proteins inside the
infected cells) but not Huh7-CD81WT. In contrast, although
there were unspecific and CD81-independent binding of
some non-E2 enveloped HCV RNA-containing particles to
the cell surfaces, these surface-bound viral particles were
not internalized and were degraded rapidly. In addition,
positive- and negative-strand HCV RNA persisted in the
infected Huh7-TfR-CD81 cells for at least 21 days after
viral uptake, and there are significant sequence differences
in the E1/E2 region between RNA from infected cells and
from the patient’s serum used for infection. Together, these
data suggest that viral replication, albeit at a low level, has
taken place in the infected cells and indicated that receptor-
mediated endocytosis is a viable route for HCV entry. In the
case of CD81, it is capable of mediating cell-surface HCV
attachment, but needs a cofactor(s) to enhance its recycling
efficiency in vivo, as the overexpression of chimeric, but not
wild-type, CD81 receptors facilitated virus entry into Huh7
cells and resulted in viral replication in the cells. Such an
endocytotic cofactor/receptors could be cell-type specific,
and therefore, would explain that HCV can infect only a few
cell types (hepatocytes, peripheral blood mononuclear cells,
T cells, and B cells) (for review see Bartenschlager and
Lohmann, 2001), despite the fact that CD81 is ubiquitously
expressed (Levy et al., 1998).
It remains to be determined whether LDLR or CD81
plays a more crucial role in the endocytosis of HCV or if
they can complement each other. One possibility is that
these two receptors play different roles during the course
of infection since they appear to bind HCV particles with
different surface conformations. Indeed, using a vesicular
stomatitis virus (VSV)-HCV-pseudotyped virus, Meyer
et al. (2000) found that LDLR is important for HCV-E1-
pseudotype virus infectivity, whereas CD81 determines
the infectivity of HCV-E2-pseudotype virus. Alterna-
tively, the ability of CD81 to bind specifically to E2
glycoprotein instead of lipoprotein-coated HCV particles
may suggest that it plays a more important role in medi-
ating viral exocytosis rather than endocytosis. The chi-
meric CD81 receptors characterized here may be used to
test this hypothesis. In addition, by allowing efficient
HCV entry into cells, this system may also be useful in
studying the mechanisms for HCV replication and pack-
aging, or in establishing more permissive cell culture or
small animal HCV models.
of primers. RNA extracted from the patient’s serum was also used as a template for RT-PCR (Serum). Neg. and pos. controls represented RT-PCR products
obtained from RNA of untransfected 293T cells and 293T cells that were transfected with cDNA encoding a HCV full-length genome, respectively. Cellular
GAPDH mRNA was used to check that a similar number of cells was used for RNA extraction and all RT-PCR products were visualized under UV light
after ethidium bromide staining. (B) The deduced amino acid sequences (E1/E2 region, 114 amino acids) of individual clones obtained from RNA extracted
from infected Huh7-TfR-CD81 cells at 21 days (P3) are compared to that obtained from RNA extracted from the patient’s serum used for infection (Serum).
Negative-1 to -6 represent sequences of RT-PCR products obtained using negative-strand RNA extracted from infected Huh7-TfR-CD81 cells that showed
amino acid differences from Serum. *Negative-1 and -2 sequences were observed in two independent clones. Positive-1 to -5 represent sequences of RT-PCR
products obtained using positive-strand RNA extracted from infected Huh7-TfR-CD81 cells that showed amino acid differences from Serum. Amino acid
identity is indicated with dots and nonconsensus is indicated by the amino acid single-letter code.
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Materials and methods
Cell lines
The human embryonic kidney cell line, 293, bearing the
large T antigen from SV40 (293T) was purchased from
American Type Cell Collection (Manassas, VA, USA).
HepG2, U937 cells were also purchased from American
Type Cell Collection. The hepatoma cell line, Huh7, was
obtained from Japan Health Sciences Foundation (Chou-ku,
Osaka, Japan). Huh7, 293T, and U937 were cultured at
37°C in 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM) containing 1 g/L glucose, 2 mM L-glutamine, 1.5
g/L sodium bicarbonate, 0.1 mM nonessential amino acids,
0.1 mg/ml streptomycin, and 100 U penicillin, and 5% fetal
bovine serum (FBS) (HyClone, Utah, USA). HepG2 was
cultured similarly using Eagle’s minimal essential medium
with the same additives plus 1 mM sodium pyruvate. All
reagents were purchased from Sigma (St. Louis, MO, USA)
unless otherwise stated.
Primers
All primers used in this study are listed in Table 1 and
were synthesized by Genset Singapore Biotech (Singapore).
Generation of wild-type and chimeric CD81 expression
constructs
cDNA of human full-length wild-type CD81 (CD81WT)
was obtained by RT-PCR (primers C1 and C2, Table 1)
from total cellular RNA of U937 cells and cloned into
BamHI/EcoRI sites of pcDNA3.1 (Invitrogen). For
CD81-transferrin receptor chimera (TfR-CD81), the N-ter-
minus cytoplasmic domain was obtained by PCR from the
full-length transferrin receptor cDNA (primers C3 and C4,
Table 1) and ligated to the N-terminus of pcDNA3-
CD81WT (HindIII, BamHI). For CD81-LDLR chimera, the
C-terminus cytoplasmic domain of LDLR was obtained by
RT-PCR using total cellular RNA of HepG2 cells as tem-
plate (C5 and C6, Table 1). PCR product was then ligated to
the C-terminus of a pcDNA3-CD81WT clone whose stop
codon has been removed by PCR amplification (EcoRI,
NotI). RNA was extracted with RNeasy columns (Qiagen,
Valencia, CA, USA), and reverse transcription and PCR
were performed using Superscript II RNase H reverse
transcriptase (Gibco-BRL, Gaithersburg, MD, USA) and
Vent DNA polymerase (New England Biolabs, Beverly,
MA, USA), respectively. Schematic representations of the
different forms of CD81 used in this study are shown in Fig.
1A and B.
Transfection of mammalian cells and selection of stable
cell lines
Transient transfection experiments were performed using
Effectene transfection reagent from Qiagen, according to
manufacturer’s protocol. To generate the various stable
CD81-expressing clones, 20 g of DNA was mixed with
about 5  106 Huh7 cells and electroporated at 0.25 kV
using a Bio-Rad (Hercules, CA, USA) gene pulser machine.
Cells were selected by growing in 1 mg/ml geneticin
Fig. 7. Preclearing of patient’s serum with an anti-HCV E2 antibody
abolished the internalization of HCV particles. After the overlay experi-
ments shown in Fig. 5A, the remaining serum from patient A was refrozen
at 80°C and later, thawed again for these experiments. (A) Serum was
immunoprecipitated with an anti-HCV E2 antibody or anti-c-myc antibody
(negative control) and protein A/G beads. After washing, RNA was ex-
tracted from the immunocomplexes on the protein A/G beads and analyzed
at different dilutions for the presence of positive-strand HCV RNA. Some
HCV RNA were immunoprecipated by both antibodies (neat, lanes 2 and
6) but significantly (10–30) more HCV RNA were bound to anti-HCV
E2 antibody (lanes 6 to 9) than anti-c-myc antibody (lanes 2 to 5). RT-PCR
products were still detected when the RNA immunoprecipitated by anti-E2
antibody was diluted 10 and 30 but no RT-PCR products were ob-
served for anti-c-myc antibody at these dilutions. DNA marker was loaded
in lane 1 (nt, nucleotides). (B) RT-PCR was performed to assay for the
presence of positive-strand viral transcripts in Huh7 stables clones after
they were exposed to serum from patient A for 8 h at 37°C, washed, and
allowed to grow for another 7 days. Positive-strand RT-PCR products were
observed in Huh7-TfR-CD81 (lane 4) and Huh7-CD81-LDLR (lane 1)
cells but not in untransfected Huh7 (lane 2) or Huh7-CD81WT cells (lane
3). No positive-strand RT-PCR products were observed in Huh7-TfR-
CD81 cells overlaid with serum that was precleared with an anti-HCV E2
antibody (lane 5), while positive-strand RT-PCR products were still ob-
served when the cells were overlaid with serum that was precleared with
control anti-c-myc antibody (lane 6). Cellular GAPDH mRNA was used to
check that a similar number of cells was used in the experiments.
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(Gibco-BRL) and single colonies were isolated and ana-
lyzed for surface expression by fluorescence-activated cell
sorting (FACS) analysis.
FACS analysis
For FACS analysis, cells were washed once with PBS,
followed by incubation with PBS containing 0.2 mM EDTA
for 10 min to detach the cells from the plates. Then, the cells
were harvested, washed twice with PBS, and resuspended at
1 106 cells/ml. One-half a milliliter of cells was incubated
with a mouse anti-human CD81 antibody (10 g/ml anti-
hCD81; BD PharMingen, San Diego, CA, USA or Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or an isotype-
matched control for 30 min at 4°C, washed, and reincubated
with a goat anti-mouse antibody conjugated with phyco-
erythrin (Sigma). Cells were washed as before and analyzed
on a Becton–Dickinson flow cytometer (San Jose, CA,
USA). Live cells were gated and a total of 10,000 events
were collected per analysis. For stable Huh7 cells express-
ing wild-type CD81, high-expressing clones were isolated
by FACS-sorting. FACS analysis to determine the endoge-
nous expression levels of transferrin and LDL receptors
were performed similarly using antibodies from BD Phar-
Mingen and Oncogene Research Products (Cambridge, MA,
USA), respectively.
Internalization of CD81 antibody
Cells (5  105) were plated on six-well plates and al-
lowed to settle overnight. Then 0.5 ml of 10 g/ml of
anti-hCD81 monoclonal antibody was overlaid onto the
cells for 1 h at 37°C. The plate was then cooled on ice for
10 min with three washes of cold PBS before any unbound
antibody was removed. For experiments that involved the
removal of surface-bound antibodies, the cells were further
incubated with cold acid (0.2 M acetic acid (pH 2.0)/0.5 M
NaCl (Haigler et al., 1980)) for 5 min, followed by PBS
washes. Finally, cells were harvested after trypsinization
and directly lysed in Laemmli’s SDS buffer (containing 10
mM DTT (Sigma) and 20 mM beta-mercaptoethanol (BDH
Laboratory Supplies, Poole, UK)) and subjected to Western
blot analysis. Briefly, total protein was separated on a 10%
SDS–PAGE and transferred to nitrocellulose Hybond C
membrane (Amersham-Pharmacia Biotech UK, Bucking-
hamshire, UK). Then, the membrane was blocked with 5%
non-fat milk and incubated with goat anti-mouse horserad-
ish peroxidase (HRP) conjugated antibody (Pierce, Rock-
ford, IL, USA) for 1 h, followed by detection using an
enhanced chemiluminescence method (Pierce). Western
blot analysis for the detection of heat shock protein 70
(Hsp70) was carried similarly using specific primary anti-
body (anti-Hsp70, StressGen Biotechnologies Corp., CA,
USA), followed by HRP-conjugated secondary antibodies
and detected as above. Quantification of all autoradiographs
was carried out on a Bio-Rad densitometer.
Indirect immunofluorescence
To detect the surface expression of receptors by indirect
immunofluorescence, live cells grown on permanox slide
(Nalge Nunc International, Naperville, IL, USA), were in-
cubated with anti-hCD81 antibody (4 g/ml) in PBS 
0.5% BSA (Sigma) for 3 h at 4°C, followed by extensive
washes with cold PBS  0.5% BSA. Then, a FITC-conju-
gated goat anti-mouse antibody (Santa Cruz) was added for
2 h at 4°C, and the cells were washed extensively and fixed
with 3.7% formaldehyde (BDH Laboratory Supplies) for 10
min at room temperature, and the slides were mounted.
To follow the path of internalized antibody after endo-
cytosis, anti-hCD81 antibody (10 g/ml) was layered onto
live cells for 1 h at 37°C, followed by cold acid wash as
described above. Then, the cells were fixed with 3.7%
formaldehyde for 10 min at room temperature and perme-
abilized with 0.2% Triton-X (BDH Laboratory Supplies) for
10 min and blocked with PBS  1% BSA for 30 min.
Finally, the cells were incubated with a FITC-conjugated
goat anti-mouse antibody for 1 h at room temperature to
detect any internalized anti-hCD81 antibody. Then, the cells
were washed and the slides were mounted. All slides were
mounted with FluorSave reagent (Oncogene Research Prod-
ucts) and analyzed on a MRC1024 laser confocal micro-
scope (Bio-Rad).
Binding and internalization of E2 (aa 384–661) protein
The sequence of HCV E2 cDNA from aa 384–661 was
PCR-amplified from the HCV genome of HCV-S1 of ge-
notype 1b (Lim et al., 2001; GenBank Accession No.
AF356827) and cloned into the BamHI and EcoRV sites of
pSecTagC from Invitrogen. The C-terminal of E2 was not
included in this construct because it was reported that this
region is highly hydrophobic and can anchor E2 to the
endoplasmic reticulum, preventing secretion of the protein
(Selby et al., 1994). Primers used for PCR were C7 and C8
(Table 1). This construct, pSecTagC-E2, expresses E2 with
a myc-epitope and a (His)6 motif at the C terminus.
293T cells were transiently transfected with pSecTagC-E2
and the culture medium was harvested after 3 days. Using
this construct, which contained the signal peptide from the
V-J2-C region of the mouse IgG kappa-chain, virtually all
the expressed E2 protein was secreted into the culture me-
dium. Secreted E2 proteins in the culture medium were
captured onto NTA-nickel sepharose beads (Qiagen) by
incubation for at least 4 h at room temperature. The beads
were washed with 10 mM HEPES, 150 mM NaCl, and 1%
NP-40 (BDH Laboratory Supplies) and then aliquots were
heated at 100°C for 5 min in Laemmli’s SDS buffer without
or with reducing agents (10 mM DTT and 20 mM beta-
mercaptoethanol), and subjected to Western blot analysis
as described above. An anti-c-myc monoclonal antibody
(Santa Cruz) or an anti-HCV E2 monoclonal antibody (Austral
Biologicals, San Ramon, CA, USA) was used for detection.
265Y.-J. Tan et al. / Virology 308 (2003) 250–269
For overlay experiments, the E2-bound beads were
washed with PBS instead and E2 protein eluted from the
beads with 1 M imidazole (Sigma), followed by centrifugal
filtration (Biomax column, 10-kDa cutoff, Millipore, Bed-
ford, MA, USA) to exchange the buffer into PBS. Finally,
E2 protein in PBS with 1% BSA was overlaid onto live cells
for 4 h at 37°C. Cells were washed three times with cold
PBS, harvested after trypsinization, and directly lysed in
Laemmli’s SDS buffer (containing 10 mM DTT and 20 mM
beta-mercaptoethanol) to release any E2 protein associated
with the cells. Total E2 protein (surface-bound and inter-
nalized) associated with each clone was determined by
Western blot analysis (as described above) using anti-c-myc
antibody. Expression of endogenous beta-actin (anti-beta-
actin antibody, Sigma) was used to check for equal loading.
To observe the internalization of E2 protein into the
cells, E2 protein was overlaid onto live cells (grown on
permanox slide) for 4 h at 37°C, followed by cold acid
wash, before the cells were fixed and permeabilized. Inter-
nalized E2 protein was detected by staining with an anti-c-
myc monoclonal antibody followed by a FITC-conjugated
goat anti-mouse antibody. Acid wash, fixation, and perme-
abilization of cells were performed as described above.
Sera from HCV-infected patients
Serum samples were obtained from two patients with
HCV infection being followed at the National University
Hospital, Singapore. The amount of HCV RNA in these two
sera was quantified by the branched DNA method (Quan-
tiplex HCV-RNA assay; Chiron Corp., Emeryville, CA,
USA) at the Molecular Diagnosis Centre, National Univer-
sity Hospital, Singapore, and any remaining samples were
stored at 80°C. The viral loads of the serum of patient A
and B were 63.4  106 equivalents/ml and 120  106
equivalents/ml, respectively. After it was confirmed that no
further testing of these samples was necessary, they were
transferred, with the administrating doctor’s consent, to our
laboratories for the experiments carried out in this article.
Internalization of HCV particles
For overlay experiments, 5  105 cells were plated on
6-cm plates and allowed to settle overnight. The cells (about
50% confluent) were washed twice with DMEM medium
without FBS, followed by addition of diluted serum (10 l
of serum with 450 l of DMEM medium without FBS). The
cells were left for 8 h at 37°C to allow the binding and
internalization of virus particles. After that, one set of the
cells was washed with cold DEPC-treated PBS and the cells
were harvested by scraping. Another set of cells was washed
first with cold DEPC-treated PBS, followed by cold acid
(0.2 M acetic acid (pH 2.0)/0.5 M NaCl (Haigler et al.,
1980)) for 5 min and then PBS washes, and the cells har-
vested.
Another set of cells was overlaid with patient’s serum as
above except that 100 l of serum (diluted with 900 l
DMEM medium without FBS) was used for each plate.
Again, the cells were left for 8 h in a 37°C incubator, 5%
CO2, after which they were washed extensively with
DMEM without FBS. Finally, 2 ml of complete DMEM
medium was added to the cells and the cells were returned
to the incubator. Two days later, the cells were trypsinized
and all the cells were transferred to a 15-cm plate for further
incubation. Another 5 days later, the cells were trypsinized
and collected and washed twice with DEPC-treated PBS
and used immediately or stored at 80°C. In some cases,
10% of the trypsinized cells was transferred to a new plate
and allowed to grow for another 7 days (P1) before the cells
were again trypsinized and harvested (14 days, P2), and the
process was repeated for another week (21 days, P3).
For treatment with detergent, sterile-filtered deoxy-
chloate solution (Sigma, 0.5% stock) was added to 1 ml of
diluted serum (100 l of serum with 900 l DMEM without
FBS) to give a final concentration of 0.05% and this was
allowed to mix at 4°C for 4 h. Bio-beads (Bio-Rad) were
prepared as described in manufacturer’s protocol (using
DEPC-treated PBS) and 2 ml bead slurry was added to the
detergent-treated serum and incubated overnight at 4°C.
This step removed the detergent from the serum to prevent
any toxic effects on the cells. Then the beads were allowed
to settle by gravity and the supernatant carefully removed
and overlaid onto the cells for 8 h at 37°C, before the cells
were washed and cultivated for 7 days and analyzed as
described above.
For the preclearing experiments, 1 ml of diluted serum
(100 l of serum with 900 l DMEM without FBS) was
incubated with 10 g of either anti-HCV E2 antibody (Aus-
tral Biologicals) or anti-c-myc antibody (Santa Cruz) and
100 l of protein A/G beads (Oncogene Research Products)
overnight at 4°C. After that, the beads were spun down and
the supernatant overlaid onto the cells for 8 h at 37°C,
before the cells were washed and cultivated for 7 days and
analyzed as described above. The remaining protein A/G
beads were washed twice with DEPC-treated PBS and total
RNA was extracted from the immunocomplexes on the
protein A/G beads with Trizol LS (Gibco-BRL), according
to the manufacturer’s protocol, and resuspended in 30 l of
DEPC-treated water. Each RNA sample (neat, 10, 30,
and 100 dilutions) was tested for positive-strand HCV
RNA as described below.
RNA extraction, reverse transcription, and nested PCR
For each 6-cm plate of cells that was overlaid with the
patient’s serum, total RNA was extracted with Trizol
(Gibco-BRL) according to the manufacturer’s protocol and
resuspended in 20 l of DEPC-treated water. After the
extraction of RNA, total cellular protein was also extracted
from the Trizol–cell mixture according to the manufactur-
er’s protocol and used for Western blot analysis as de-
scribed above. RNA from 10 l of the patient’s serum was
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also extracted with Trizol LS (Gibco-BRL) and resuspended
in 20 l of DEPC-treated water. For cells that were culti-
vated for 7 or more days, total RNA from 3  106 cells
(approximately half of the total cells) was extracted and
resuspended in 60 l of DEPC-treated water.
For each sample, 5 l RNA was treated with 5 U RNase-
free DNase I (Roche Diagnostics, GmbH, Mannheim, Ger-
many) at 37°C for 1 h, followed by inactivation of DNase I
by heating at 100°C for 10 min. For the detection of posi-
tive-strand HCV RNA, 5 l DNase I treated RNA was then
reverse transcribed at 42°C for 1 h using the antisense
primer 209 (Table 1), dNTP (Roche), and 100 U of Super-
script II RNase H reverse transcriptase (Gibco-BRL) in a
final volume of 10 l, followed by inactivation by heating
at 70°C for 15 min. This product was used as template for
nested PCR. The first PCR reaction was carried out using
the external primers (antisense primer 209 and sense primer
939, Table 1) with 5 l template in a total volume of 25 l
and the second round of PCR was then performed using
internal primer set (antisense primer 211 and sense primer
940, Table 1) with 1 l of the first PCR reaction as template
in a total volume of 25 l. These primers corresponding to
the HCV 5NCR sequences and in another set of experi-
ments, primers corresponding to the HCV E1/E2 region
were used instead: antisense primer E1E2R1 for reverse
transcription, followed by external primers E1E2R1 and
E1E2F1 for the first PCR reaction, and internal primers
E1E2R2 and E1E2F2 for the second PCR reaction (Table
1).
For the detection of negative-strand HCV RNA, the
tagged primer method devised by Lanford et al. (1994) was
used. Five microliters of DNase I treated RNA was reverse
transcribed as above except that the tagged primer,
TAGNC1 (sense, Table 1), was used instead. After inacti-
vation of the reverse transcriptase, the template was further
treated with 0.1 mg/ml of RNase A (Sigma) at 37°C for 30
min to degrade any remaining RNA. Then, 5 l of the
template was used for the first round of PCR using TAG and
antisense 209 (Table 1). This was followed by a second
round of PCR using internal primer set, 940 and 211 (Table
1), using 1 l of the products from the first PCR as template.
These primers, corresponding to the HCV 5NCR se-
quences, and in another set of experiments, primers corre-
sponding to the HCV E1/E2 region, were used instead:
TAGNC1 for reverse transcription, followed by TAG and
antisense E1E2R1 for the first PCR reaction, and internal
primers E1E2R2 and E1E2F2 for the second PCR reaction
(Table 1).
Cellular GAPDH mRNA was used to check that similar
number of cells was used in each experiment. For this
purpose, 0.5 l of DNase I treated RNA was reverse tran-
scribed as above except that oligo(dT) (Roche) was used
instead. Then 1 l of the template was used for one round
of PCR using the primers, GAPDHfor and GAPDHrev
(Table 1).
All PCR were performed using Titanium Taq DNA poly-
merase from Clontech Laboratories Inc. (Palo Alto, CA,
USA) or High Fidelity PCR kit from Roche, and PCR
conditions are as follows: 95°C for 2 min, followed by 35
cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 1 min, and
a final extension at 72°C for 10 min. Amplified products (all
25 l) from the second round of PCR for positive- and
negative-strand viral transcripts, or from one round of PCR
for GAPDH, were separated on a 3% agarose gel and
visualized under UV light after staining with ethidium bro-
mide.
Southern hybridization
For Southern blotting, the negative-strand RT-PCR prod-
ucts were separated on agarose gel and blotted onto Hy-
bond-N membrane (Amersham-Pharmacia Biotech). Hy-
bridization was carried out with an oligonucleotide,
corresponding to sequence in the 5NCR (HCVprobe, Table
1), 5-labeled with [32P]dATP (NEN Life Science Prod-
ucts, Boston, MA, USA) by T4 polynucleotide kinase (New
England Biolabs). ExpressHyb hybridization solution
(Clonetech) and 10 g/ml of sheared salmon sperm DNA
(Sigma) were used for the hybridization. The filters were
incubated at 60°C for 14–16 h, after which they were
washed twice with 2 SSC–0.1% SDS and twice with 1
SSC–0.1% SDS, at room temperature, and finally twice in
0.1 SSC–0.1% SDS, at 60°C. The filters were wrapped in
Saran Wrap and exposed to autoradiography films at80°C
for 12–24 h.
TA cloning and sequence analysis
After separation on agarose gel, positive- or negative-
strand RT-PCR products were excised and purified using
the QIAquick kit (Qiagen) and ligated into pCRII-TOPO
vector using the TA cloning kit from Invitrogen. At least 20
clones from each ligation were sequenced (with both M15
forward and reverse primers). Sequences were aligned using
MegAlign software (DNAStar Inc., Madison, WI, USA).
DNA sequencing of all constructs was carried out by the
core facility at the Institute of Molecular and Cell Biology.
Two hundred nanograms of the double-stranded templates
and 10 ng of the primer were used for the dideoxy method
with the Taq DyeDeoxy terminator cycle sequencing kit and
the automated DNA sequencer 373 from PE Applied Bio-
systems (Foster City, CA, USA).
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